Penumbra (PEN) Projected to Post Earnings on Tuesday

Penumbra (NYSE:PEN) will likely be releasing its Q4 2025 results before the market opens on Tuesday, February 17th. Analysts expect Penumbra to post earnings of $1.12 per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, February 23, 2026 at 4:00 PM ET.

Penumbra Trading Down 0.5%

Penumbra stock opened at $339.32 on Tuesday. Penumbra has a 52-week low of $221.26 and a 52-week high of $362.41. The company has a market cap of $13.29 billion, a P/E ratio of 81.18, a P/E/G ratio of 2.10 and a beta of 0.81. The company has a quick ratio of 4.18, a current ratio of 6.73 and a debt-to-equity ratio of 0.02. The business has a 50-day simple moving average of $325.10 and a two-hundred day simple moving average of $282.71.

Insider Activity

In other Penumbra news, EVP Johanna Roberts sold 1,800 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $300.06, for a total transaction of $540,108.00. Following the sale, the executive vice president directly owned 64,736 shares of the company’s stock, valued at $19,424,684.16. This trade represents a 2.71% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Harpreet Grewal sold 186 shares of the business’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $312.64, for a total value of $58,151.04. Following the completion of the transaction, the director owned 8,230 shares in the company, valued at $2,573,027.20. The trade was a 2.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 33,172 shares of company stock worth $10,015,279. 5.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada lifted its holdings in shares of Penumbra by 35.8% in the first quarter. Royal Bank of Canada now owns 19,332 shares of the company’s stock worth $5,169,000 after buying an additional 5,092 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in Penumbra by 209.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 272 shares of the company’s stock valued at $70,000 after acquiring an additional 184 shares during the last quarter. Cerity Partners LLC increased its holdings in Penumbra by 22.3% in the 2nd quarter. Cerity Partners LLC now owns 10,030 shares of the company’s stock valued at $2,574,000 after acquiring an additional 1,829 shares during the last quarter. California Public Employees Retirement System lifted its stake in Penumbra by 7.9% in the 2nd quarter. California Public Employees Retirement System now owns 61,027 shares of the company’s stock worth $15,661,000 after purchasing an additional 4,491 shares in the last quarter. Finally, Daiwa Securities Group Inc. bought a new position in shares of Penumbra during the 2nd quarter valued at about $1,137,000. 88.88% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

PEN has been the subject of several recent research reports. William Blair lowered shares of Penumbra from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 15th. Citigroup downgraded shares of Penumbra from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $350.00 to $374.00 in a research report on Thursday, January 15th. Needham & Company LLC cut Penumbra from a “buy” rating to a “hold” rating in a report on Friday, January 16th. Wells Fargo & Company reiterated an “equal weight” rating and set a $374.00 target price on shares of Penumbra in a research report on Thursday, January 15th. Finally, Canaccord Genuity Group cut Penumbra from a “buy” rating to a “hold” rating and upped their price target for the stock from $359.00 to $374.00 in a research report on Tuesday, January 20th. Four investment analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $358.00.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.